Form 8-K - Current report:
SEC Accession No. 0001193125-24-271609
Filing Date
2024-12-05
Accepted
2024-12-05 16:50:29
Documents
13
Period of Report
2024-12-02
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d914736d8k.htm   iXBRL 8-K 24300
  Complete submission text file 0001193125-24-271609.txt   149892

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ikt-20241202.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20241202_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20241202_pre.xml EX-101.PRE 11712
15 EXTRACTED XBRL INSTANCE DOCUMENT d914736d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 241529727
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)